CompletedPhase 2NCT00679354
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Studying Anaplastic astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Tobey MacDonaldChildren's Oncology Group
- Intervention
- cilengitide(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2008 – 2011
Study locations (20)
- Kaiser Permanente-Oakland, Oakland, California, United States
- University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States
- Lombardi Comprehensive Cancer Center at Georgetown University, Washington D.C., District of Columbia, United States
- Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
- Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
- Newark Beth Israel Medical Center, Newark, New Jersey, United States
- New York University Langone Medical Center, New York, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
- Children's Hospital Medical Center of Akron, Akron, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Oregon Health and Science University, Portland, Oregon, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Palmetto Health Richland, Columbia, South Carolina, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00679354 on ClinicalTrials.govOther trials for Anaplastic astrocytoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07448480Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant GliomasBlokhin's Russian Cancer Research Center
- RECRUITINGEARLY PHASE1NCT06333899Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionNationwide Children's Hospital
- RECRUITINGPHASE1, PHASE2NCT05956821Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of AgeUniversity of Miami
- ACTIVE NOT RECRUITINGPHASE1NCT06614855A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant GliomaJames Markert, MD
- RECRUITINGPHASE2NCT06161974Study of Olutasidenib and Temozolomide in HGGRigel Pharmaceuticals
- RECRUITINGPHASE2NCT05843253Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantNationwide Children's Hospital
- RECRUITINGNCT05839379Targeted Pediatric High-Grade Glioma TherapyNationwide Children's Hospital
- RECRUITINGPHASE2NCT06264388DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic AstrocytomaAshish Shah